Palisade Bio Inc. is a clinical-stage biopharmaceutical company focused on developing oral therapies for inflammatory and fibrotic diseases. Its lead program, PALI-2108, is a once-daily oral phosphodiesterase-4 (PDE4) inhibitor prodrug designed for targeted activation in the ileum and colon, with an emphasis on localized treatment of inflammatory bowel disease, including ulcerative colitis and Crohn’s disease. The company’s current pipeline also includes additional gastrointestinal-focused programs aimed at protecting the intestinal barrier and addressing postoperative complications. Palisade Bio works with research and development partners to advance its drug candidates through clinical studies and product development, positioning the company within the specialty biopharmaceutical segment of the healthcare market.
Website4600 South Syracuse Street
Denver, CO, 80237
United States
Palisade Bio (NASDAQ:PALI) said it is advancing its lead drug candidate, PALI-2108, into Phase II studies for ulcerative colitis and Crohn’s disease after completing its Phase I program. Chief Executive Officer JD Finley said PALI-2108 is a once-daily oral phosphodiesterase 4, or PDE4, inhibitor de
Palisade Bio (PALI) has obtained clearance from Health Canada for its global phase 2 study evaluatin
Palisade Bio (PALI) said the US Food and Drug Administration cleared its investigational new drug ap
ASCENTRA-CD expected to enroll approximately 60 patients with moderate to severe Crohn’s diseaseFirst patient dosing targeted for Q1 2027; primary...
Investors talking about PALI also mention
What share of all stock conversation is about PALI?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Attention | 0% new | 0% 0 | 0% +0 | 0% +0 |
Of the messages about PALI that take a side, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Bullish | — | 73.91% -8.35 | 84.96% -15.04 | 81.97% +39.72 | ||
| Bearish | — | 26.09% +8.35 | 15.04% +15.04 | 18.03% -39.72 |
Of the messages about PALI that carry a topic, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Announcements | 100% | 88.24% | 97.73% | 45.83% | ||
| Technical Analysis | 0% | 11.76% | 2.27% | 16.21% | ||
| Analysts | 0% | 0% | 0% | 21.05% | ||
| Controversies | 0% | 0% | 0% | 0.45% | ||
| Earnings | 0% | 0% | 0% | 0.03% | ||
| Macro | 0% | 0% | 0% | 16.43% |
Of the messages about PALI, what share comes from each group?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Regulars | 100% | 87.5% | 68.2% | 44.5% | ||
| Newcomers | 0% | 12.5% | 31.8% | 55.5% |